Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients  by White, C.A. et al.
Cost of applying the K/DOQI guidelines for bone
metabolism and disease to a cohort of chronic
hemodialysis patients
CA White1, J Jaffey2 and P Magner2,3
1Division of Nephrology, Department of Medicine, Queen’s University, Kingston, Ontario, Canada; 2The Ottawa Health Research Institute,
Ottawa, Ontario, Canada and 3Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
Hyperphosphatemia is a common feature of advanced
chronic kidney disease (CKD) and is treated routinely with
oral calcium-based phosphate binders. In 2003, the National
Kidney Foundation Kidney Disease Outcomes and Quality
Initiative (K/DOQI) published Clinical Practice Guidelines
(CPGs) for the treatment of Bone Metabolism and Disease
in CKD. These advocate broad usage of expensive
non-calcium-based phosphate binders such as sevelamer.
This study was designed to determine the cost of
implementation of the K/DOQI CPGs as they pertain to
phosphate binding in a large Canadian hemodialysis (HD)
unit. Laboratory and medication data for all chronic HD
patients at the Ottawa Hospital were reviewed (n¼ 416).
Patients meeting each of the relevant K/DOQI guidelines
were identified. Where guidelines would recommend a
switch to non-calcium binders, equivalent sevelamer doses
were estimated. The cost of implementing each guideline
was then calculated individually and an estimate total cost of
implementing all the guidelines was derived. Overall, 53%
(222) patients fulfilled at least one criterion for sevelamer use.
The yearly cost of implementation of the K/DOQI guidelines
at this center was estimated at $ 500 605 (American dollars).
Given the significant cost, widespread adoption of the
K/DOQI CPGs for Bone Metabolism and Disease should await
the publication of compelling data demonstrating significant
improved outcomes in patients treated with sevelamer.
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Advanced chronic kidney disease (CKD) is complicated by
metabolic bone disease, hyperphosphatemia, and abnormali-
ties of parathyroid hormone (PTH) secretion.1 The sequelae
of these include bone pain and fracture, hypertension, and
extra-osseous calcification, including vascular calcification
that has been implicated in the excess cardiovascular
mortality of CKD patients.2 Hyperphosphatemia itself is also
associated with an increased risk of mortality.3
Dietary phosphate (PO4) restriction and oral PO4 binders
comprise the initial and principal steps in the management of
hyperphosphatemia.1 Aluminum-based PO4 binders were
once used extensively to treat hyperphosphatemia. These
were largely abandoned when aluminum was found to
contribute to anemia, myopathies, dementia, and low-
turnover bone disease.4 Aluminum was replaced by the
calcium-based PO4 binders, calcium acetate, and calcium
carbonate (CaCO3). There is now growing concern that these
may contribute to or accelerate the vascular calcification
observed in hemodialysis (HD) patients.1,5–9 More recently,
non-calcium and non-aluminum-based binders such as
sevelamer have been developed. As yet, there are no published
randomized controlled trials (RCTs) comparing sevelamer to
calcium-based phosphate binders with clinical endpoints
such as cardiovascular events and mortality.
In 2003, the US National Kidney Foundation (NKF)
Kidney Disease Outcomes Quality Initiative (K-DOQI)
published Clinical Practice Guidelines (CPGs) for Bone
Metabolism and Disease in CKD. These CPGs advocate the
use of sevelamer across a range of common clinical scenarios
in CKD (Table 1). Sevelamer is significantly more costly than
the calcium-based salts. By analyzing patients in our large
HD program, we have determined the economic impact of a
‘common sense’ application of the phosphate-binding
recommendations of the NKF K/DOQI CPGs for Bone
Metabolism and Disease in CKD.
RESULTS
In December 2003, there were 470 patients receiving chronic
HD at the Ottawa Hospital or at one of its affiliated satellite
units. Fifty-four were excluded (28 for sevelamer use, 10 for
multiple missing lab values, and 16 for acute hospitalizations
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or previous parathyroidectomy) leaving the final cohort of
416 patients who were included in the analysis.
The biochemical results and medication use of the cohort
are shown in Table 2. On average, calcium and phosphate
control were within K/DOQI targets.1 Average intact PTH
(iPTH) was slightly above recommended target of
16.5–33 pmol/l.1 In December, only 53 and 75% of patients
met the K/DOQI calcium and phosphate targets and only
25% were within iPTH targets.1 Fifty-six percent were
prescribed calcitriol. The majority of patients (84%) were
prescribed CaCO3 as a phosphate binder. There was a greater
than 400 mg of elemental calcium/day discrepancy between
the medication database and the self-reported CaCO3 dose in
31% of patients.
Table 3 shows the number of patients who fulfilled the
K/DOQI guideline criteria for sevelamer and the economic
impact of calcium substitution with sevelamer. A total of 222
(53%) patients met at least one the K/DOQI requirements for
substitution of CaCO3 with sevelamer. The most common
indication for sevelamer (133 patients, 32%) was a dose of
elemental calcium greater than 1.5 g/day (guideline 5.5). In
comparison, only 36 patients (9%) qualified owing to
hypercalcemia (guideline 5.6) and 79 patients (19 %)
qualified for two successive iPTH values below 16.5 mmol/l
(guideline 5.6). Of the relevant guidelines, only guideline 5.6
was labeled ‘evidence’ – based by the K/DOQI work group.
Conversion of all calcium above 1.5 g/day to sevelamer
would cost on average an extra $4.93 per patient per day or
$239 230 yearly for the cohort. The cost of substitution for
hypercalcemic patients was estimated at $88 936 yearly for
the cohort. The total estimated yearly cost for guideline
adherence was $500 605.
The results are only slightly different using the prescribed
dose of calcium instead of the self-reported dose. The criteria
for sevelamer use was met by 231 patients with an associated
cost of $6.28 per patient per day or $529 522 yearly for the
cohort.
DISCUSSION
This study reveals the significant cost associated with the
application of the NKF K/DOQI CPGs for Bone Metabolism
and Disease in CKD in a single Canadian HD program. This
expense is in addition to the already high cost of maintaining
this cohort on HD estimated at $19 123 227 yearly.10
Assuming the mineral metabolism parameters of the patients
enrolled in this study are similar to those of other Canadian
HD populations, the yearly cost of guideline adherence for
Canada’s 13 620 HD patients11 would exceed 16 million
dollars.
Thirty-three percent of this patient cohort qualified for
sevelamer use based on ingestion of calcium exceeding 1.5 g/
day (guideline 5.5). This translates to a cost of $239 230
yearly for the cohort. The rationale for choosing 1.5 g/day as
the calcium threshold is not well explained in the NKF K/
DOQI CPGs and it is difficult to extrapolate from the
available literature what constitutes a safe dose of calcium.
Evidence supporting a detrimental effect of calcium ingestion
first emerged from observational studies linking calcium salt
ingestion to radiographic evidence of extra-osseous calcifica-
tion.6,7,11 The Treat to Goal study randomized 200 prevalent
Table 1 | The K/DOQI CPGs for bone metabolism and disease in CKD that suggest sevelamer use in HD patients
Guideline and
level of evidence Guideline summary Criteria for patient identification
5.5 Opinion Dose of elemental Ca should be less then 1.5 g/d. Identify patients with elemental Ca dose greater than 1.5 g/d.
5.6 Evidence Ca-based binders should not be used if plasma iPTH is less
than 16.5 pmol/l on two consecutive measures.
Identify patients with a plasma iPTH less than 16.5 pmol/l who
are not on vitamin D.
5.6 Evidence Ca-based binders should not be used if serum Ca greater
than 2.54 mmol/l.
Identify patients with a serum Ca greater than 2.54 mmol/l and a
serum PO4 greater than 1.78 mmol/l who are not on vitamin D or
patients with serum Ca greater than 2.54 mmol/l who are on less
than 1.5 g/d of elemental Ca and who are not on vitamin D or
patients with serum Ca greater than 2.54 mmol/l with a plasma
iPTH greater than 33 pmol/l.
13c Opinion Decrease or eliminate Ca-based binders and vitamin D if
plasma iPTH is less than 11 pmol/l.
Identify patients with a plasma iPTH less than 11 pmol/l who are
not on vitamin D.
Ca, calcium; CKD, chronic kidney disease; CPG, clinical practice guideline; d, day; HD, hemodialysis; iPTH, intact parathyroid hormone; K/DOQI, Kidney Disease Outcomes
Quality Initiative; PO4, phosphate.
Table 2 | Characteristics of the HD cohort (n=416)
Age (yrs) 68717
Male gender (%) 250 (60)
Number at satellite HD unit (%) 239 (57)
Serum Ca (mmol/l)a 2.470.2
Serum PO4 (mmol/l)
b 1.670.5
Plasma iPTH (pmol/l)c
31.2738.4
Number taking calcitriol (%) 234 (56)
Number taking CaCO3 (%) 350 (83)
Mean daily elemental Ca dose (g)d 1.570.9
Number with 0.4 g/d or greater difference between medication
database and patient reported elemental Ca dose (%)
131 (31)
Number with serum Ca less than 2.37 mmol/l (%)e 221 (53)
Number with serum PO4 less than 1.78 mmol/l (%)
e 314 (75)
Number with plasma iPTH between 16.5–33.0 pmol/l (%)e 103 (25)
Ca, calcium; CaCO3, calcium carbonate; d, day; HD, hemodialysis; iPTH, intact
parathyroid hormone; PO4, phosphate; yrs, years.
aMean corrected serum Ca values (October, November, and December).
bMean serum PO4 values (October, November, and December).
cMean of two most recent iPTH values.
dMean dose of those taking CaCO3.
eBased on December values.
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HD patients to sevelamer or to calcium salts.5 Those on
sevelamer had significantly lower median percent change in
coronary artery (6 vs 25%) and aortic (5 vs 28%)
calcification scores as measured by electron beam computed
tomography at 1 year. Similar results in another smaller RCT
have been reported.9 The relationship between calcification
scores and clinical cardiovascular disease or mortality in HD
patients has not been well established. One small observa-
tional study demonstrates a nonsignificant association
between a coronary artery calcification score by electron
beam computed tomography of greater than 200 and death in
104 chronic HD patients.12 On multivariate analysis, the
coronary artery calcification score was only marginally
demonstrated to be an independent predictor of death with
a relative risk of 1.001 (1.000–1.002).12 It should be
acknowledged that K/DOQI accords an ‘opinion’ label to
guideline 5.5 and, in its accompanying discussion, recom-
mends that ‘cost’, amongst other things, be taken into
account by the clinician.
Preliminary results of the Dialysis Clinical Outcomes
Revisited study have been reported in abstract form (J Am Soc
Nephrol; 281(A): 2006). In this RCT of 2100 HD patients,
patients were assigned to receive sevelamer or calcium
salts and were followed for 3 years. The major clinical end
points were death and cardiovascular events. Preliminary
results do not show a significant reduction in mortality or
cardiovascular events in those treated with sevelamer. Some
benefit was reported in subgroups: patients over 65 years old
had a 22% risk reduction in all cause mortality (P¼ 0.03);
patients who were still alive and who continued therapy for
more than 2 years, had a 34% reduction in all cause mortality
(P¼ 0.02).
The absence of published data documenting any benefit of
sevelamer on clinical end points precludes a formal economic
analysis. However, a simpler cost trade-off analysis does
permit an estimatation of the clinical impact required for
sevelamer to achieve cost effectiveness. The cost in US dollars
of a myocardial infarction, stroke, coronary artery bypass
graft surgery, and peripheral angioplasty/surgery for non-HD
patients in Canada has been estimated at $4913, $11 977,
$10 763 and $3571, respectively.13 Thus, in our cohort of 416
patients, every year sevelamer would need to prevent either
102 myocardial infarctions, 42 strokes, 47 coronary artery
bypass graft surgeries, 140 peripheral revascularizations or
some combination of these in order to be cost neutral. It is
difficult to envision any therapy in HD patients able to
achieve this degree of benefit. In fact, these numbers vastly
exceed the cohort’s expected event rate. Based on the results
of a large RCT in HD patients with clinical cardiovascular
end points, we would anticipate only 29 strokes and
21 coronary artery bypass graft surgeries in this cohort over
a 3-year period.14
Calcium avoidance in HD patients in the face of
widespread vascular calcification and cardiovascular disease
seems intuitive. However, vascular disease in CKD is highly
complex with multiple putative contributors.15 Traditional
cardiovascular disease risk factors such as diabetes, hyperten-
sion, and dyslipidemia are highly prevalent in the CKD
population.15 In addition to abnormal mineral metabolism, a
number of other CKD-specific risk factors such as inflam-
mation, oxidative stress, proteinuria, and uremic toxins are
also postulated to play a role.15,16 As a result, it is plausible
that a single intervention such as calcium avoidance would
have no significant effect on cardiovascular outcomes in the
HD population. The preliminary results of the Dialysis
Clinical Outcomes Revisited trial (J Am Soc Nephrol; 281(A):
2006) appear to support this notion.
One could postulate that the increased cost associated
with sevelamer use may be partially offset by the reduced
need for 3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitors therapy. HD patients have a high prevalence of
dyslipidemia.17 In the Treat to Goal study, sevelamer
significantly reduced the total cholesterol, the low-density
lipoprotein cholesterol and the non-high-density lipoprotein
cholesterol levels.5 However, The 4D (’Deutsche Diabetes
Dialyse Studie) a large RCT with clinical cardiovascular
outcomes, did not show a benefit of 3-hydroxy-3-methylglu-
taryl-coenzyme A reductase inhibitors in diabetic HD
patients.14 Even before the publication of the 4D study,
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
were uncommonly used in HD patients,14,18–20 perhaps
reflecting the low prevalence of significantly elevated
low-density lipoprotein levels in this population17 and the
inverse relationship between cholesterol levels and mortality in
end-stage renal disease.21 One can reasonably postulate that
utilization rates will only decrease following the publication of
Table 3 | Number of patients meeting the K/DOQI CPGs for bone metabolism and disease in CKD and estimated cost of
guideline adherence
Guideline and
level of evidence Guideline summary Number of patients (%)
Extra cost of sevelamera
(US$/day/patient)
Extra cost of sevelamera
(US$/year/cohort)
5.5 Opinion Elemental Ca greater than 1.5 g/d 133 (32%) 4.93 239 230
5.6 Evidence Plasma iPTH less than 16.5 pmol/l
on two consecutive measures
79 (19%) 7.90 227 802
5.6 Evidence Serum Ca greater than 2.54 mmol/l 36 (9%) 6.77 88 936
13c Opinion Plasma iPTH less than 11 pmol/l 95 (23%) 7.75 268 866
Any of above 222 (53%) 6.18 500 605
Ca, calcium; CKD, chronic kidney disease; CPG, clinical practice guideline; iPTH, intact parathyroid hormone; K/DOQI, Kidney Disease Outcomes Quality Initiative.
aCalculated by subtracting the cost of CaCO3 from the cost of the substituting sevelamer.
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4D. For these reasons, the cost impact of improved lipid profile
with sevelamer would likely be minimal.
There are certain instances in which it is reasonable,
perhaps even desirable, to prescribe sevelamer. For example a
hypercalcemic hyperphosphatemic patient may indeed bene-
fit from avoidance of calcium containing phosphate binders
as set out in guideline 5.6. Other circumstances in which
sevelamer may be beneficial include patients with calcific
uremic arteriolopathy (guideline 5.7).
Manns et al.22 have also examined the economic impact of
broadly applying the K/DOQI CPGs for Bone Metabolism
and Disease recommendations, and have published results
with similar conclusion to ours. In their Canadian cohort of
499 dialysis patients, 51% met at least one guideline, whereas
in their American cohort 64% fulfilled at least one guideline.
Using the average dose of sevelamer required to achieve
phosphate control in the Treat to Goal study,5 they report an
estimated yearly cost of $3644 US per patient. We have
estimated a much lower cost of $1203 US per patient. This
present study differs significantly in the way estimated
sevelamer doses were derived. We generated a conversion
algorithm tailored to each particular guideline and we also
applied each patient’s actual calcium dose to establish the
appropriate equivalent sevelamer dose. We felt this strategy
would provide a more accurate estimation of sevelamer
requirements, which is reflected in this study’s lower
projected cost of guideline adherence. In addition, we
attempted to model a ‘real world’ approach to mineral
metabolism abnormalities (Table 1). Patients meeting the
K/DOQI criteria for sevelamer use were not included if there
were other reasonable strategies to attain the recommended
targets. For example, patients who were hypercalcemic but
who had PO4 values within target were not included as a
simple dose reduction of calcium could potentially restore
their biochemistry to within acceptable ranges. We also
sought to determine as accurately as possible the actual
ingested calcium dose for each patient by conducting patient
interviews. Interestingly, we found significant discrepancies
between patient-reported doses and database doses (Table 2).
Other strengths of this study include the inclusion of the
both in-hospital and satellite unit HD patients ensuring that
both ‘healthy’ and ‘sick’ HD patients were represented. In
addition, the medication data was retrieved 2 months
following the publication of the guidelines. This timeliness
ensures that there would be little change in practice patterns
by the attending nephrologists resulting from their familiarity
with the specifics of the guidelines. The low sevelamer
utilization rate (26 patients) confirms the lack of adoption of
the guidelines at the time of the analysis.
Weaknesses of this study should be noted. Firstly, this
analysis is very conservative. It did not take into account
adequacy of control of plasma PO4. Twenty-five percent of
the cohort had PO4 levels above the recommended target.
Also, patients for whom there was no documented verbal
dose of calcium were considered to not be taking any.
Together, these would lead to an underestimation of
sevelamer requirements and cost. Secondly, the cohort only
included patients on HD. Cost of guideline adherence for
patients on peritoneal dialysis can therefore not be estimated.
Thirdly, this was a single center study, which could limit its
external validity. Finally, this study provides only a snap shot
of mineral metabolism control over a period of 3 months.
A patient may meet a guideline criterion 1 month and not the
next. The impact of this on our results is difficult to predict.
There is currently no international body overseeing the
process by which CPGs are developed. In the United
Kingdom, the National Institute for Clinical Evidence has
established guidelines for CPG development.23 The Ontario
Government Ministry of Health in partnership with the
Ontario Medical Association uses an instrument called the
Appraisal of Guidelines Research and Evaluation to review
published guidelines.24 Both National Institute for Clinical
Evidence and Appraisal of Guidelines Research and Evalua-
tion incorporate economic impact as a critical step in
guideline assessment. K/DOQI does not incorporate financial
considerations in their guideline development. Whether or
not economics should be guiding principle in CPG develop-
ment is an ongoing source of discussion.22,25–29 This issue will
become increasingly important as other expensive therapies
developed specifically for patients with CKD and abnormal
mineral metabolism, such as lanthanum carbonate and
cinecalcet, become more widely available.
This study demonstrates the substantial cost of adherence
to the K/DOQI CPGs for Bone Metabolism and Disease in
CKD as they pertain to phosphate binders in HD patients.
Evidence supporting the relative benefit of sevelamer over
calcium salts is preliminary and modest in scale. This is
reflected in the ‘opinion’ label allotted to several of relevant
K/DOQI guidelines. The Canadian Society of Nephrology has
also recently published guidelines addressing oral phosphate
binders.30 These conclude that there is insufficient evidence
to recommend the use of any one particular phosphate
binder and caution that sevelamer is more expensive but not
superior at controlling serum phosphate levels. Until further
evidence emerges clearly documenting the clinical benefit of
any one phosphate binder, clinicans should consider both
economics and individual patient characteristics when
selecting a phosphate binder.
MATERIALS AND METHODS
Study population
All patients receiving thrice weekly HD at the Ottawa Hospital or
one of its affiliated satellite units for at least 3 months by December
2003 were included. Patients were excluded if they were hospitalized
for an acute illness at the time of data collection, had undergone a
parathyroidectomy, were already prescribed sevelamer, or had
multiple data points missing. The Ottawa Hospital dialysis unit
and its satellites use a computerized database system to record
patient medications and clinical information. On the day of the
December 2003 monthly blood tests, patient’s medication data, as
recorded in the medication list section of the database, was
abstracted. On the same day, the renal unit nurses asked all HD
patients or their caregivers the formulation and dose of phosphate
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binders they were taking. This was recorded in narrative form in the
computerized data base progress notes. This additional step was
included to enhance accuracy of the medication data.
Laboratory data
The results of the October, November, and December 2003 monthly
blood work (total calcium (Ca), phosphate (PO4) and albumin)
were recorded. All iPTH levels measured in 2003 were also recorded.
Calcium levels were corrected using the formula c(Ca)¼ t
(Ca)þ 0.02(40(albumin)) as recommended by K/DOQI.1 iPTH
was measured using the DiaSorin assay, which has a coefficient of
variation of 10%. Albumin was measured by the TinaQuant assay,
which has a coefficient of variation of 8%. Phosphate and calcium
were measured using the Auto chem. assay, which has a coefficient
of variation of 2%.
Analysis
The NKF K/DOQI CPGs for Bone Metabolism and Disease in CKD1
were reviewed and the relevant guidelines were selected for inclusion
(Table 1). Each guideline’s status as either ‘Opinion’ or ‘Evidence’
based was noted. Patients were identified who fulfilled the guideline
conditions that would dictate treatment with sevalamer. The three
consecutive monthly serum calcium and phosphate values were
analyzed separately.
As vitamin D therapy can contribute to PTH suppression, only
patients not prescribed vitamin D were included in the analysis of
guidelines 5.6 (iPTHo16.5 pmol/l) and 13c. Similarly, as CaCO3
and vitamin D can lead to hypercalcemia, only hypercalcemic
patients who were hyperphosphatemic (PO441.8 mmol/l) or who
were taking less than 1.5 g of elemental calcium per day and who
were not prescribed vitamin D were included in the analysis of
guideline 5.6 (Ca42.54 mmol/l). The analysis of guideline 5.6
(Ca42.54 mmol/l) also included any hypercalcemic patients with an
iPTH above the recommended target of 16.5–30 pmol/l regardless of
whether they were on vitamin D. These patients require vitamin D
to control their hyperparathyroidism. Discontinuing it in order to
control calcium levels is therefore not a viable long-term option.
The number of patients fulfilling the K/DOQI guidelines for
sevelamer by individual guideline and the total number of patients
fulfilling at least one of the guidelines were determined. The self-
reported dose of CaCO3 taken by patients meeting each guideline
was noted and used for the subsequent analysis. Patients for whom
either no dose or non-compliance was recorded by the nursing staff
were assumed to not be taking calcium.
An algorithm for substitution of CaCO3 by sevelamer was
developed to reflect the guideline recommendations (Table 4). The
dose of sevelamer required to replace the CaCO3 was then calculated
for each patient. Dose equivalency between elemental calcium and
sevelamer (1 g elemental calcium¼ 4.16 g of sevelamer) was derived
from the Treat To Goal Study, the largest published randomized
study comparing sevelamer to calcium-based binders (1). The cost
of replacing CaCO3 with sevelamer was then established. The cost of
sevelamer ($1.498/800 mg) and CaCO3 (TUMs regular 500 mg,
$0.0174/100 mg elemental calcium including 40% markup, 7%
government sales tax and 8% provincial sales tax) was obtained from
the McKesson, Canada wholesale pricing guide.31 Dispensing fees
were not included. The cost of substitution was calculated by
subtracting the cost of the CaCO3 from the cost of the replacement
sevelamer. All costs are reported in American (US) dollars. Costs in
Canadian (Cnd) dollars were converted to US dollars based on the
Bank of Canada’s nominal noon exchange rates on 1 Dec 2003
(1Cnd$¼ 0.77 US$).32
The final cost of guideline adherence was estimated as follows:
the cost of CaCO3 replacement by sevelamer was calculated for all
patients meeting guideline 5.6 (iPTHo16.5 pmol/l 2)). For the
remaining patients (all those not meeting guideline 5.6
(iPTHo16.5 pmol/l 2), those who met guideline 13c were
identified and the cost of replacing their CaCO3 by sevelamer was
tabulated. A similar calculation was then carried out for the
remaining patients (all those not meeting guidelines 13c or 5.6
(iPTHo16.5 2)) who met guideline 5.6 (Ca42.54 mmol/l).
Finally the analysis was repeated for those only meeting guideline
5.5. A total expense was then calculated by adding all of the above
costs.
As the prescribed dose of elemental calcium was lower than the
patient reported dose, which could lead to overestimation of the
true budgetary impact of conversion to sevelamer, the analysis was
repeated using the prescribed calcium dose.
The analysis was performed using SAS for Windows version 9.1.
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